Kornimate/medical-research-clean huggingface dataset:
development of a standardized reference guide for tuning adherence to dispense during a initial pharmaceutical consulting (cp ) to the patient with multiple myeloma oral chemotherapy primocure

Conditions: Multiple Myeloma

Summary: the hypothesis is that the implementation of an initial pharmaceutical consultation (pc) program based on the provision of standardized information to patients treated for multiple myeloma as a first course of chemotherapy, could optimize their compliance with the delivered per os treatment. the aim of this study is therefore to develop a standardised reference guide of information to be provided during prostate cancer in order to optimise the compliance of patients treated for multiple myeloma as a first course of chemotherapy per os.


Eligibility criteria:
inclusion criteria * the patient must be a member or beneficiary of a health insurance plan * the patient is at least 18 years old * the patient is treated for multiple myeloma, is naive to any treatment and begins a chemotherapy protocol with oral therapy and whose course of care includes a stay in the day hospital or retrocessions. criteria for non-inclusion * the subject is participating in another study * the subject is in an exclusion period determined by a previous study * the subject is under the protection of justice, guardianship or curatorship * it is impossible to give informed information about * the patient is pregnant, parturient, or breastfeeding * the patient receives a follow-up by a home nurse for the administration of oral medication * the patient is treated only with oral chemotherapy in the city * the patient has early dementia. translated with www.deepl.com/translator -
effect of liraglutide on the metabolic profile in patients with type 2 diabetes and cardiovascular disease

Conditions: Type 2 Diabetes; Cardiovascular Diseases

Summary: in an unbiased metabolomics approach with subsequent pathway analyses, the current study seeks to examine the effect of liraglutide treatment on the metabolic signature in treated patients as well as the effect of liraglutide on various echocardiographic parameters of cardiac function and rhythm profile, thus paving the way for future research to explain the effects of liraglutide on cardiovascular mortality and overall mortality in treated patients.


Eligibility criteria:
inclusion criteria: 1. type 2 diabetes 2. serum levels of hba1c ≥ 7,0% 3. age ≥ 18 years 4. patients with existing cardiovascular disease: coronary heart disease, cerebrovascular disease, peripheral vascular disease, chronic kidney disease of stage iii or chronic heart failure of nyha ii or iii) 5. written informed consent prior to study participation exclusion criteria: 1. type 1 diabetes 2. treatment with glp-1 receptor agonists or dpp-4 inhibitors within the last 4 weeks 3. patients with familiar or personal history of multiple endocrine neoplasia-type 2 or medullary c-cell cancer 4. renal impairment (egfr \< 30 ml/min) 5. occurrence of acute vascular events within 6 weeks before screening and randomization 6. known or suspected hypersensitivity to liraglutide 7. pregnant females as determined by positive (serum or urine) hcg test at screening or prior to dosing. participants of child-bearing age should use adequate contraception as defined in the study protocol. 8. lactating females 9. the subject has a history of any other illness, which, in the opinion of the investigator, might pose an unacceptable risk by administering study medication. 10. the subject received an investigational drug within 30 days prior to inclusion into this study. 11. the subject has any current or past medical condition and/or required medication to treat a condition that could affect the evaluation of the study. 12. the subject is unwilling or unable to follow the procedures outlined in the protocol. 13. the subject is mentally or legally incapacitated.

Keywords: liraglutide type 2 diabetes high cardiovascular risk myocardial infarction metabolic profile
improving health services for veterans with schizophrenia

Conditions: Schizophrenia

Summary: schizophrenia exacts a high toll on the lives of patients and their families and constitutes a major health care cost. visn 5 has placed special emphasis on improving care for veterans with severe mental disorders, an effort recently recognized by the va as a program of excellence in the care of seriously mentally ill veterans.

background: schizophrenia exacts a high toll on the lives of patients and their families and constitutes a major health care cost. visn 5 has placed special emphasis on improving care for veterans with severe mental disorders, an effort recently recognized by the va as a program of excellence in the care of seriously mentally ill veterans. objectives: this study is implementing a set of promising qoc methods for assessing qoc for schizophrenia in routine settings, using the evidence-based treatment recommendations developed under the ahcpr/nimh-sponsored schizophrenia patient outcomes research team (port). methods: a random sample of 350 persons with a schizophrenia spectrum disorder is being drawn from the visn 5 sites. patients must have more than one outpatient contact during the preceding six months. each subject will participate in two one-hour interviews, one at baseline and another six months later. an informant, psychiatrist, therapist, etc. will also be interviewed to help validate participant response. status: project work is ongoing.

Eligibility criteria:
inclusion criteria: patients must be adults currently in treatment for an axis i schizophrenia spectrum disorder (dsm295) at va. exclusion criteria:
treatment of bevacizumab and triamcinolone in treatment or macular edema secondary to crvo

Conditions: Macular Edema; Central Retinal Vein Occlusion

Summary: treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.

comparison of two groups with different treatment with registrations of outcome in bcva and complications

Eligibility criteria:
inclusion criteria: * macular edema secondary to central retinal vein occlusion * bcva worse than 20/40 * central macular \>250 mc with oct exclusion criteria: * diabetic retinopathy or other retinopathy * media opacity that does not allow following * steroid responder * diagnosed glaucoma or iop \> 21 mmhg

Keywords: macular edema central retinal vein occlusion bevacizumab triamcinolone
pentoxifylline as adjunctive therapy in patients with ulcerative colitis

Conditions: Inflammatory Bowel Diseases

Summary: the exact underlying mechanisms of ulcerative colitis (uc), an idiopathic, chronic inflammatory disease marked by diffused inflammation of the colon and rectum mucosa, are still unknown. due to genetic, immune, and environmental factors, uc is highly dependent on cellular immune reactions and exaggerated inflammatory responses. the release of several cytokines, kinins, leukotrienes, platelet-activating factor (paf), and reactive oxygen species is connected to immunological activity (ros). additionally, many of the cytokines will start an acute phase response, making the inflammation worse.


Eligibility criteria:
inclusion criteria: age ≥ 18 years both males and females will be included negative pregnancy test and effective contraception exclusion criteria: - breastfeeding significant liver and kidney function abnormalities colorectal cancer patients patients with severe uc patients taking rectal or systemic steroids known allergy to the studied medications
study of busulfan and flag conditioning regimen for allogeneic peripheral blood stem cell transplantation

Conditions: Leukemia

Summary: the purpose of this study is to determine the safety and efficacy of busulfan/flag (fludarabine, cytarabine and granulocyte colony-stimulating factor) conditioning regimen in patients with relapsed/refractory acute leukemia undergoing allogeneic peripheral blood stem cell transplantation.

allogeneic hematopoietic stem cell transplantation (allo-sct) is the only way to cure relapsed/refractory acute leukemia. busulfan/cyclophosphamide (bucy, cytarabine, busulfan, cyclophosphamide) has been a classical conditioning regimen for allo-sct. substitution of cyclophosphamide in the bucy regimen with fludarabine (buf) resulted in reduced toxicity and similar efficacy. flag (fludarabine, cytarabine and granulocyte colony-stimulating factor) is a chemotherapy regimen that has been proved to be effective for relapsed/refractory acute leukemia as salvage therapy. to reduce the relapse and improve the survival of those patients with relapsed/refractory acute leukemia who receive allo-sct, the novel conditioning regimen consisting of busulfan/flag was developed. the combination of bu and flag without interval shortens the duration of conditioning and the pneutropenic period of the patient compared with successive administration of flag followed with buf. in addition, regarding the established safety and efficacy of buf and flag, it is reasonable to expect similar safety and enhanced antileukemic efficacy for bu/flag compared with buf. in this study, the safety and efficacy of this regimen in patients with relapsed/refractory acute leukemia undergoing allogeneic peripheral blood stem cell transplantation was investigated.

Eligibility criteria:
inclusion criteria: * relapsed/refractory acute leukemia regardless of cytogenetics * all patients should aged 12 to 65 years * have matched sibling donors, ≥8/10 hla(human leukocyte antigen) matched unrelated donors or haploidentical donors * patients without any uncontrolled infections or without severe pulmonary, renal, hepatic or cardiac diseases exclusion criteria: * patients aged less than 12 years old * patients with any uncontrolled infections or with severe pulmonary, renal, hepatic or cardiac diseases * acute myeloid leukemia patients with t (15;17)

Keywords: allogeneic peripheral blood stem cell transplantation conditioning regimen acute leukemia relapsed/refractory
study of intravenous aflibercept in combination with folfiri in japanese patients with metastatic colorectal cancer

Conditions: Colorectal Neoplasms; Neoplasm Metastasis

Summary: the primary objective is to determine the dose of aflibercept to be further studied in combination with irinotecan/5-fluorouracil/isovorin (folfiri) in japanese patients with metastatic colorectal cancer. secondary objectives of this study are to assess the safety profile of aflibercept, to determine the pharmacokinetics of aflibercept, to make a preliminary assessment of antitumor effects.


Eligibility criteria:
inclusion criteria: * patients with histologically or cytologically proven malignant tumor of the colon or rectum which is metastatic and inoperable. * patients must have received at least one prior line of treatment with any standard of care, who have failed the treatment, or who have not been eligible for standard of care for safety reasons. exclusion criteria: * treatment with chemotherapy, hormone therapy, radiotherapy, surgery, blood products, or any investigational agent within 28 days. * ecog performance status\>1 * anticipated need for a major surgical procedure or radiation therapy during the study. * uncontrolled malignant ascites. * history of brain metastases, spinal cord compression, or carcinomatous meningitis or new evidence of brain or leptomeningeal disease on screening ct or mri scan. * pregnant or breast-feeding women. * uncontrolled hypertension * patients who have previously been treated with aflibercept * history of abdominal fistula, gi perforation, or intra-abdominal abscess within the past 28 days. * history of hypersensitivity to any recombinant proteins, irinotecan, fluoropyrimidine or isovorin. * known dihydropyrimidine dehydrogenase deficiency. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: oxaliplatin 5-fu folinic acid
performing laparoscopic surgery for colorectal and gastric cancer outside the primary registered medical institution

Conditions: Colorectal Cancer; Gastric Cancer

Summary: this study investigates the safety and feasibility of performing laparoscopic surgery for colorectal and gastric cancer inside versus outside the primary registered medical institution under multi-sites practice (msp) policy. this is a single practitioner, retrospective comparative study. the endpoints are peri-operative outcomes, pathological results, and medical costs.


Eligibility criteria:
inclusion criteria: * age between 18 and 100 years * diagnosed as colorectal cancer or gastric cancer * undergoing laparoscopic surgery between 2016-2020 performed by dr feng exclusion criteria: * emergency procedure * without histopathological result of malignancy * conventional open surgery
evaluation of the ponto bone anchored hearing system in a pediatric atresia population

Conditions: Hearing Loss; Conductive Hearing Loss; Atresia

Summary: the purpose of this study is to in a proactive manner collect high quality data from a pediatric patients who have undergone a bone anchored hearing solution, using the ponto bhx implant, in clinical practice. this to further increase the knowledge of using the system.


Eligibility criteria:
inclusion criteria: * patients who have decided to undergo a bone anchored hearing surgery * diagnosed with atresia * signed informed consent * patients between 2,5 - 18 years of age * patients eligible for one stage surgery exclusion criteria: * not fluent in swedish or english; subject and/or legal guardian * unwillingness to participate in follow up visits
us-guided sapb versus espb on acute and chronic pain after vats

Conditions: Postoperative Pain; Video-Assisted Thoracoscopic Surgery; Serratus Anterior Plane Block; Erector Spinae Plane Block; Acute Pain; Chronic Pain

Summary: postoperative acute and chronic pain is frequently observed in patients undergoing video assisted thoracoscopic surgery (vats). this prolongs the discharge time of patients and increases the frequency of postoperative pulmonary complications. recently, alternative analgesic methods such as thoracic paravertebral block (tpvb), erector spinae plane block (espb), and serratus anterior plane block (sapb) which are thought to have less side effects than thoracic epidural analgesia, have been used. among these methods, ultrasound (us) guided tpvb is the most preferred method. in addition, espb and sapb application is increasing in patients undergoing vats. in the literature, the number of cases performed with espb and sapb and randomized controlled prospective studies with espb and sapb are increasing. in this study, it is planned to compare the effects of us-guided sapb and espb on postoperative acute and chronic pain in patients undergoing vats.


Eligibility criteria:
inclusion criteria: * age between 18 and 65 years * american society of anesthesiologists physical status i-ii-iii * body mass index between 18-30 kg/m2 * patients undergoing elective video assiste thoracoscopic surgery exclusion criteria: * advanced cancer * history of chronic analgesic therapy * history of local anesthetic allergy * infection in the intervention area * patients with bleeding disorders

Keywords: serratus anterior plane block erector spinae plane block acute pain chronic pain
cd19/20 bispecific nanobody-derived car-t cells in b cell lymphoma

Conditions: B-Cell Lymphoma Stage I; Refractory; Relapsed

Summary: evaluation the safety and efficacy of cd19/cd20 bispecific car-t cells in patients with relapsed/refractory b cell lymphoma

cart cell therapy has become the treatment of choice for patients with relapsed/ refractory b cell lymphoma. currently, car-t cells approved for relapsed/refractory b-cell lymphoma are mainly car19-t cells. nearly half of patients who relapse after treatment with car19-t cells are caused by tumor cell antigen escape. dual-target car-t cells targeting cd19 and cd20 may reduce the recurrence rate after treatment. this study was to evaluate the efficacy and safety of cd19/cd20 bispecific car-t cells in patients with relapsed/refractory b cell lymphoma.

Eligibility criteria:
inclusion criteria: * expected lifetime\>3 months * cd19/cd20 positive relapsed/refractory b cell lymphoma * kps\>70 * at least one measurable lesion according to recist 1.1 * enough function of hear, liver, kidney and bone marrow * no history of severe allergies * no other history of malignancy * no other diseases that conflict with this regimen * no serious mental illness * patient or family member sign informed consent exclusion criteria: * pregnant or lactating women * severe infectious or viral disease * active b or c viral hepatitis * patients who have used large amounts of glucocorticoids or other immunosuppressive agents during the last 4 weeks * participated in other clinical studies in the last 3 months, or have been treated with other gene products * others not appropriate to participate in this study examined by the investigators
assesment of intermediate vision after bil cataract surgery

Conditions: Cataract

Summary: the goal of this observational study is to learn about the intermediate and near vision in patiënts who underwent cataract surgery with a specific technique, called "bag in the lens". the main question it aims to answer is whether patiens who underwent this type of cataract surgery have better intermediate vision without spectacle correction than patients who underwent the classic lens in the bag cataract surgery. participants will: * have to read with and without spectacle correction at different distances (4 meters, 66 centimeters, 40 centimeters) * have to fill in 2 questionnaires about visual functioning and spectacle independance researchers will compare these values to the same values from the standard population who underwent the classic lens in the bag cataract surgery with a monofocal intraocular lens .


Eligibility criteria:
inclusion criteria: * patients of at least 18 years old * must have underwent bilateral bag in the lens cataract surgery in the university hospital brussels at least 3 months before inclusion * must not meet any exclusion criteria exclusion criteria: * prior refractive surgery (other than bag in the lens) * glaucoma * corneal opacities * moderate non proliferative diabetic retinopathy or worse * optic neuropathy * history of uveitis * amblyopia * residual post-operative astigmatism higher than 1.5 diopters (d) * best corrected visual acuity \< 1.0 * patients unable to cooperate or sign the informed consent

Keywords: bag in lens intermediate vision
quality of life after cardiac surgery

Conditions: Aortic Valve Stenosis; Mitral Valve Disease; Tricuspid Valve Disease; Aorta Disease; Coronary Artery Bypass Graft

Summary: during the last twenty years heart surgery has become safer and the number of patients having heart surgery has increased with more frail patients being offered increasingly complex surgery. heart operations often improve survival and quality of life (qol), but that is not true for all patients. regarding survival, clinicians can measure the risk to life from having a heart operation and the risk to life from not quite precisely, but clinicians have little idea about the impact of heart operations on qol, which is the outcome that patients care about most. clinicians are unable to provide patients with robust information on how an operation will affect their qol. this study will provide this information by analysing the data from patient questionnaires immediately before and after the procedure and monthly thereafter for 12 months.

the sponsor shall use existing questionnaires to measure qol in patients having major heart surgery. qol will be measured before the operation and monthly afterwards for 12 months in order to answer the following questions: 1. how does having heart surgery affect the qol immediately after the operation? 2. how long does it take patients to return to the same quality of life they had before the surgery? 3. how long does it take patients to regain any loss of quality of life due to the operation? does quality of life improve thereafter? 4. what proportion of patients will achieve a net benefit in qol? 5. are there features that can predict who will benefit in terms of qol and who will not? the sponsor will use the data to develop an electronic calculator to enable quick and robust evaluation of the impact of heart surgery on the qol of individuals. patients will then be able to give truly informed consent and to decide if they wish have surgery based on a full knowledge of both surgical risk and the potential impact on qol.

Eligibility criteria:
inclusion criteria: * euroscore ii ≥ 3% or euroscore logistic of ≥ 6% * patients undergoing routine/ urgent cardiac surgery * patients must have the ability to provide informed consent exclusion criteria: * patients undergoing salvage or emergency operations
a randomized trial of lenient versus strict arm instruction post cardiac device surgery

Conditions: Post-Op Complication

Summary: the purpose and objectives of this study is to investigate whether reducing the existing arm restrictions on patients who receive cardiac implantable electronic devices (cied) will result in an improved patient experience post operatively and reduce complication rates. there are multiple and varied arm restriction instructions given to patients receiving cied's with limited universally accepted protocols or advice on restrictions for patients following surgery. restrictions such as arm immobilization, showering and weight lifting, in addition to contradictory advice between various hospitals and physicians, can negatively affect patient quality of life and increase patient anxiety with no current evidence for benefit. a cluster cross over randomized trial has been designed to test the comparative effectiveness of lenient vs strict arm restrictions for all patients receiving implantable devices. instructions within both arms of this study are considered within reasonable practice in canada. all arm restriction instructions and parameters will be embedded within epic, nurses will teach the restriction in addition they will be provide to the patients via printed epic discharge summaries. further links will be embedded in the after visit summary (afs) printouts and my chart for patients in epic. these instructions will be changed every 7 months, as per the crossover design of the trial. additionally, both arms will utilize interactive voice recognition (ivr) to provide patients with further reminders and instruction on arm restrictions. all patients are given standard of care instructions for follow up and complication assessment through our device clinic and 24/7 on call nursing program.

the purpose and objectives of this study is to investigate whether reducing the existing restrictions on patients post cied will result in an improved patient experience post operatively and reduce complication rates. results from this study will create standardized, postoperative arm restriction recommendations more uniform between various hospitals. hypothesis: the investigators hypothesize that outcomes of the post cied implanted patients given lenient arm restriction will be non-inferior to those with prolonged arm restriction at reducing a combined primary endpoint of lead dislodgement, device infection, clinically significant pocket hematoma, upper limb dvt and frozen shoulder. clinical relevance: the investigators anticipate that patients with minimal (lenient) arm restriction will have similar postoperative complication rates compared to the prolonged arm restriction. should this hypothesis be proven, this will greatly improve patient quality of life post cied with less stringent restrictions.

Eligibility criteria:
inclusion criteria: * all patients undergoing device surgery which includes implantation of at least one new endovascular lead exclusion criteria: * standalone cied generator replacement

Keywords: cardiac implantable electronic device arm restriction post-operative infection dislodgement hematoma dvt